linjc16/ctgov huggingface dataset:
Imaging Techniques in Body Magnetic Resonance Imaging MRI

Study Overview
=================
Brief Summary
-----------------
Any patient already receiving a scheduled MR scan of the body for any clinical indication will be eligible for this program.

Detailed Description
-----------------
If patients agree to participate in this program, it would require only a slightly longer examination time. This time would vary according to the body area/organ being visualized but would not exceed 30 minutes over the length of the clinical examination. Volunteers are eligible if they are willing to undergo an MR examination. Patients would not be required to make any additional visits beyond their clinically-indicated visits. The study duration would vary according to the body area/organ visualized but would not exceed 30 minutes over the length of the clinical examination. Volunteers would be required to keep one study appointment to include one MR imaging examination. There will be no interruption to the standard care given to patients who participate in this trial since the clinical portion of their examination will be completed prior to the study portion of the exam.

Official Title
-----------------
Body Magnetic Resonance (MR) Imaging Techniques

Conditions
-----------------
Clinically Indicated MR Imaging

Intervention / Treatment
-----------------
* Device: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female clinically scheduled to undergo MR Imaging at Johns Hopkins Medical Institutions Exclusion Criteria: Contraindications to MR Imaging

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: MRI|Magnetic resonance imaging|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Magnetic resonance signal | Magnetic resonance imaging acquires signal from the human body. The signal will be measured at the time of the patient study. The amount of signal change will be measured between subjects. | One Hour |
UCLA FOCUS Family Resiliency Training Research Study

Study Overview
=================
Brief Summary
-----------------
The study will examine the effectiveness of an eight session, manualized individual family resiliency training (IFRT) for families with one OEF/OIF/OND veteran in promoting better family communication relating to return to post military life.

Official Title
-----------------
UCLA FOCUS (Families OverComing Under Stress) Family Resiliency Training Research Study

Conditions
-----------------
Veteran Families, Family Communications, Civilian Life Reintegration

Intervention / Treatment
-----------------
* Behavioral: FOCUS Individualized Family Resiliency Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: OEF/OIF/OND Veteran adult family member cohabiting with significant other for 6 months or more at least one child age 5 to 17 years Exclusion Criteria: active case with Child Protective Services conditions or substance use that limits ability to fully participate in the research program

Ages Eligible for Study
-----------------
Minimum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Immediate intervention<br>Subjects are randomized to receive immediate intervention of the 8 session FOCUS IFRT | Behavioral: FOCUS Individualized Family Resiliency Training<br>* Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.<br>|
| Active Comparator: Waitlisted<br>Subjects are randomized to be waitlisted for 4 months, re-assessed and then receive intervention of the 8 session FOCUS IFRT | Behavioral: FOCUS Individualized Family Resiliency Training<br>* Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement on standardized behavioral health assessment scales |  | 4-6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OEF, Veteran families, OIF, OND, Resiliency, Psycho educational training, Stress, Military
Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas

Study Overview
=================
Brief Summary
-----------------
This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology and genetic data. This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

Detailed Description
-----------------
Precise classification based on molecular and genetic biomarkers/subgroups for gliomas is challenging. This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and genetic data (Whole exome sequencing, RNA sequencing, proteomics, etc). This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

Official Title
-----------------
Survival Significance and Clinical Characteristics of Molecular Pathology and Genetic Variation in Brain Gliomas

Conditions
-----------------
Glioma, Molecular Sequence Variation, Genetic Change

Intervention / Treatment
-----------------
* Diagnostic Test: Glioma groups based on molecular pathology or genetic variation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must have radiologically and histologically confirmed diagnosis of primary glioma Life expectancy of greater than 3 months Must receive tumor resection Must have sufficient fresh frozen tissues for NGS Signed informed consent Exclusion Criteria: No gliomas No sufficient amount of tumor tissues for detection of molecular pathology Patients who are pregnant or breast feeding Patients who are suffered from severe systematic malfunctions Do not have sufficient fresh frozen tissues for NGS

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Glioma groups based on molecular pathology or genetic variation|Patients with newly diagnosed glioma that receive tumor resection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival (OS) | The length of time from enrollment until the time of death (OS, overall survival) | From enrollment to death of patients. Estimated about 5 years. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Survival, Subgroup
LEVEL Trial: Correction of Inguinal Hernia, Endoscopic Versus Lichtenstein

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare laparoscopic total extraperitoneal and open mesh repair of inguinal hernia, with regard to hospital stay, postoperative pain, quality of life, postoperative recovery and return to daily activities, complications and recurrences

Official Title
-----------------
LEVEL Trial: Correction of Inguinal Hernia, Endoscopic Versus Lichtenstein. A Randomised Controlled Clinical Trial.

Conditions
-----------------
Inguinal Hernia

Intervention / Treatment
-----------------
* Procedure: Lichtenstein procedure
* Procedure: TEP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: informed consent age > 18 years inguinal hernia(primary, recurrence or bilateral) elective procedure Exclusion Criteria: Scrotal hernia Prostatectomy, Pfannenstiehl-incision, pre-peritoneal surgery in history Participation in other trial Pregnancy Communicative or cognitive restrictions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Procedure: Lichtenstein procedure<br>* open surgical procedure for inguinal hernia correction<br>|
| Active Comparator: 2<br> | Procedure: TEP<br>* Total Exta Peritoneal procedure for inguinal hernia correction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hospital stay |  | 7 days | 
| postoperative pain |  | 6 weeks | 
| return to work |  | 6 weeks | 
| quality of life |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| operating time |  | 1 day | 
| operating costs |  | 1 week | 
| complication |  | 1 month | 
| mortality |  | 5 years | 
| total costs |  | 1 month | 
| recurrence |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
groin, inguinal, hernia, lichtenstein, TEP
Predictive Factors for the Development of Osteonecrosis After the Treatment of the Developmental Dislocated Hip

Study Overview
=================
Brief Summary
-----------------
Several risk factors for the development of osteonecrosis of the femoral head following treatment of developmental dislocated hip have been reported. The need for further research with a large-enough sample size including statistical adjustment of confounders was demanded. The purpose of the present study was to find reliable predictors of osteonecrosis in patients managed for developmental dislocation of the hip and to evaluate if delayed treatment increased the risk of residual acetabular dysplasia requiring secondary surgeries.

Official Title
-----------------
Predictive Factors for the Development of Osteonecrosis After the Treatment of the Developmental Dislocated Hip. A Comparison of Early Open Reduction Versus Late Open Reduction With Combined Pemberton and Femoral Osteotomies

Conditions
-----------------
Predictors of Osteonecrosis of the Femoral Head After Treatment of the Dislocated Hip

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Follow-up > 3 years Exclusion Criteria: teratological hip dislocation neuromuscular disease previous open reduction at another medical institution

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Closed reduction < 12 months of age<br> | |
| Open reduction < 12 months of age<br> | |
| Open reduction with concomitant osteotomies > 12 months fo age<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Osteonecrosis of the femoral head |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary reconstructive procedures due to residual acetabular dysplasia |  |  |
Long-term PAS in Rehabilitation After SCI

Study Overview
=================
Brief Summary
-----------------
The investigators have recently shown in two pilot incomplete SCI patients that long-term paired associative stimulation is capable of restoring voluntary control over some paralyzed muscles and enhancing motor output in the weak muscles (1). In this study, the investigators will administer long-term paired associative stimulation to incomplete SCI patients in a long-term manner, keeping each patient in the study for as long as continuous improvement is observed.

Official Title
-----------------
Long-term Paired Associative Stimulation in Rehabilitation of Spinal Cord Injury Patients

Conditions
-----------------
Spinal Cord Injuries

Intervention / Treatment
-----------------
* Device: long-term paired associative stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: incomplete SCI Exclusion Criteria: epilepsy metal inclusion in the head area pacemaker hearing device high intracranial pressure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: incomplete SCI patients<br> | Device: long-term paired associative stimulation<br>* Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daniels and Worthingham's Muscle Testing |  | 2 days after the last stimulation session | 
| Daniels and Worthingham's Muscle Testing |  | 1 month after the last stimulation session |
Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate that orally administered itraconazole, a commonly used antifungal medication, can inhibit Hedgehog pathway signaling in patients with esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC).

Official Title
-----------------
Feasibility of Itraconazole as a Targeted Therapy for Inhibition of Hedgehog Pathway Signaling in Patients With Esophageal Cancer

Conditions
-----------------
Esophageal Cancer

Intervention / Treatment
-----------------
* Drug: Itraconazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Clinical diagnosis of esophageal cancer, including gastroesophageal junction cancer Exclusion Criteria: Patients unwilling or unable to provide informed consent Coagulopathy that precludes safe endoscopic/surgical procedure (platelet count <100,000/mm3, INR>1.5) Esophageal varices Comorbidity (e.g. pulmonary, cardiac, renal, or liver disease) that precludes safe participation in the study QTc>450 ms LFT's>3xULN Pregnancy Allergy to itraconazole History of symptomatic congestive heart failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Itraconazole<br>Itraconazole 300 mg po bid for 14-17 days | Drug: Itraconazole<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inhibition of Hedgehog pathway signaling as measured by real-time PCR. | mRNA expression levels as measured by real-time PCR of Hedgehog pathway ligands and target genes will be compared between baseline and post-itraconazole treatment. | 2-3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inhibition of VEGFR2 pathway signaling as measured by Western blot | Protein expression levels of phosphorylated VEGFR2 will be compared between baseline and post-itraconazole treatment. | 2-3 weeks |
Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.

Detailed Description
-----------------
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.

Official Title
-----------------
Multicenter, Single-blind, Randomized, Intraindividual Study of the Safety and Efficacy of Magnevist Gadopentetate Dimeglumine (Magnevist® Injection) at 0.1 and 0.2 mmol/kg for the Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

Conditions
-----------------
Myocardial Infarction

Intervention / Treatment
-----------------
* Drug: Magnevist (Gadopentetate dimeglumine, BAY86-4882)
* Drug: Magnevist (Gadopentetate dimeglumine, BAY86-4882)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 8 weeks post-documented myocardial infarction (heart attack) Exclusion Criteria: History of radiation therapy to the chest Clinically unstable Any contraindication for MRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 2<br> | Drug: Magnevist (Gadopentetate dimeglumine, BAY86-4882)<br>* One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight<br>|
| Experimental: Arm 1<br> | Drug: Magnevist (Gadopentetate dimeglumine, BAY86-4882)<br>* One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative measurement of the total area of delayed enhancement |  | 30 min post injection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative measures of area of delayed enhancement and signal intensities |  | At 5, 10 and 20 minutes post injection | 
| Semiquantitative measures of area of delayed enhancement |  | At 5, 10, 20 and 30 minutes post injection | 
| Presence of delayed enhancement |  | At 5,10 and 20 minutes post injection | 
| Wall motion endpoints |  | Pre-injection | 
| Safety |  | From baseline to 24h follow-up of second imaging |
Retinal Venous Pressure and ET-1 in Patients With Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
Measurement of the circulation in patients with diabetes mellitus and establish a link between retinal venous pressure (RVP) and endothelin (ET-1)levels.

Detailed Description
-----------------
Diabetic retinopathy and maculopathy are the main causes of visual loss. Hyperglycemia as the main risk factor of diabetic retinopathy induced damage to retinal capillaries. These in turn lead to hypoxia in the tissue and promote the release of VEGF (vascular endothelial growth factor) , which in turn increases the vascular pathology. Simultaneously, there is an increased expression of endothelin (ET-1). Endothelin increases vascular tone and regulates the micro-and macro-vascular remodeling. In ocular blood flow perfusion pressure plays an important role. While in healthy eyes a spontaneous retinal venous pulsation is frequently observed, this is significantly less frequent in diseased eyes. An increased venous pressure lowers the ocular perfusion pressure, and increases the transmural pressure. A measurement of the retinal venous pressure and the hormone ET-1 in the blood will give us a better knowledge of the circulatory changes and their relationship to diabetes.

Official Title
-----------------
Measurement of Retinal Venous Pressure and Endothelin-1 in Patients With Diabetes Mellitus

Conditions
-----------------
Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetes mellitus type I or II no diabetic retinopathy Exclusion Criteria: known diabetic retinopathy acute or chronic inflammation of the eyes narrow angle glaucoma minority

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetes patients<br>Patients with diabetes mellitus type I + II, without diabetic retinopathy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantification of retinal venous pressure (RVP) |  | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantification of ET-1 in correlation with RVP |  | 30 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes mellitus, retinal venous pressure, endothelin-1